Text Size
522 studies found for:    revlimid

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
2 Active, not recruiting Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
3 Recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination with azacitidine
4 Completed Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Condition: Cutaneous Lupus Erythematosus (CLE)
Intervention: Drug: lenalidomide (Revlimid®)
5 Recruiting Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Condition: HIV-1 Infection
Interventions: Drug: Part A: lenalidomide dose escalation;   Drug: Part B: lenalidomide;   Drug: Part B: lenalidomide placebo
6 Completed
Has Results 		Dasatinib in Combination With Revlimid (and Dexamethasone)
Condition: Multiple Myeloma
Interventions: Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
7 Active, not recruiting Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Melphalan, Prednisone, Lenalidomide;   Drug: Cyclophosphamide, Prednisone, Lenalidomide;   Drug: Lenalidomide, dexamethasone
8 Recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
9 Recruiting Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Revlimid
10 Unknown † Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL;   Untreated;   Front-line;   First-Line;   Initial Therapy
Intervention: Drug: Lenalidomide and Rituximab
11 Not yet recruiting Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
Condition: Multiple Myeloma
Interventions: Drug: Vorinostat;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Unknown † Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride;   Drug: Lenalidomide (Revlimid®)
13 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
14 Recruiting Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
15 Terminated Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: CC-5013;   Drug: liposomal doxorubicin
16 Terminated Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
Condition: Graft-versus-Host Disease
Intervention: Drug: Lenalidomide
17 Active, not recruiting Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Revlimid
18 Recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
19 Terminated Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Rituximab
20 Completed
Has Results 		Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: Lenalidomide
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years